TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding RNA-based compound designed to provide a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results